Cost-Utility Analysis of Varenicline, an Oral Smoking-Cessation Drug, in Japan

Ataru Igarashi (), Hiroki Takuma, Takashi Fukuda and Kiichiro Tsutani

PharmacoEconomics, 2009, vol. 27, issue 3, 247-261

Abstract: Objectives: To conduct a cost-utility analysis of two 12-week smoking-cessation interventions in Japan: smoking-cessation counselling by a physician compared with use of varenicline, an oral smoking-cessation drug, in addition to counselling. Methods: A Markov model was constructed to analyse lifetimemedical costs and QALYs from the perspective of the healthcare payer. The cycle length was 5 years. Both costs and QALYs were discounted at 3% annually. The cohort of smokers was classified by sex and age, and we assumed that smokers started smoking at the age of 20 years and received smoking-cessation therapy at the ages of 30, 40, 50, 60 or 70 years (five separate models were run). The healthcare costs and QALYs were calculated throughout the term until the age of 90 years. In the base-case analysis, success rates of varenicline plus counselling and counselling alone were assumed to be 37.9% and 25.5%, respectively, in male smokers, and 22.2% and 16.1%, respectively, in female smokers, based on a randomized controlled trial conducted in Japan. Both univariate and probabilistic sensitivity analyses were conducted. Results: Prescribed varenicline was shown to be more effective and less costly than smoking-cessation counselling alone. Varenicline would save direct medical costs of Japanese Yen (¥)43 846 ($US381; $US1= ¥115; Oct 2007) and generate an increase of 0.094 QALYs in male smokers. In females the incremental costeffectiveness ratio was ¥346 143 per QALY gained. Varenicline is estimated to save ¥23.7 billion ($US206 million) of the medical costs for tobacco-associated diseases for the whole population. Overall savings are ¥9.5 billion. Sensitivity analyses suggested the robustness of the results. Conclusion: As with any data of this nature, there is some uncertainty in the results and further research is warranted. However, based on the results of this pharmacoeconomic evaluation, varenicline, the first non-nicotine, oral treatment developed for smoking cessation, appears to be cost effective andmay contribute to future medical cost savings in Japan. Copyright Adis Data Information BV 2009

Date: 2009
References: View complete reference list from CitEc
Citations: View citations in EconPapers (1)

Downloads: (external link)
http://hdl.handle.net/10.2165/00019053-200927030-00007 (text/html)
Access to full text is restricted to subscribers.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:pharme:v:27:y:2009:i:3:p:247-261

Ordering information: This journal article can be ordered from
http://www.springer.com/economics/journal/40273

DOI: 10.2165/00019053-200927030-00007

Access Statistics for this article

PharmacoEconomics is currently edited by Timothy Wrightson and Christopher I. Carswell

More articles in PharmacoEconomics from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().